Table 3.
Treatment response and oncological outcome
| Patient | Tumor site, histology and size | Sunitinib dose | RT dose | Resection margin | RECIST | % non-viable tissue | Follow-up status (and time), events (months after ED) |
|---|---|---|---|---|---|---|---|
| 1 | lower extremity, myxofibrosarcoma, 11 cm | 25 | 50.4 | R0 | stable disease | 30 % | NED (29mo), LR resected (19 mo) |
| 2 | lower extremity, dediff. lipo, 8 cm | 25 | 50.4 | R0 | stable disease | 95 % | AWD (36 mo), Soft tissue mets (15 mo) |
| 3 | Retroperitoneal, dediff. lipo, 15 cm | 25 | 50.4 | R1 | stable disease | 75 % | NED (28 mo) |
| 4 | Retroperitoneal, dediff. lipo, 12 cm | 25 | 50.4 | R1 | stable disease | 20 % | NED (11 mo) |
| 5 | Retroperitoneal, undiff. pleomorphic sarcoma, 14 cm | 25 | 50.4 | R2 (primary Tumor R0) | progressive disease (locally and mets) | 70 % | DOD (9 mo), Liver mets at surgery |
| 6 | Groin, Dediff. lipo, 20 cm | 25 | 50.4 | R0 | stable disease | 30 % | NED (24 mo) |
| 7 | Retroperitoneal, myxoidlipo, 5 cm | 37.5 | 50.4 | R0 | partial response | 50 % | NED (20 mo) |
| 8 | lower extremity, synovial sarcoma, 8 cm | 37.5 | 50.4 | R0 | stabledisease | 100 % | AWD (23 mo), Lung mets (15 mo) |
| 9 | chest wall, undiff. pleomorphic sarcoma, 5 cm | 37.5 | 50.4 | R0 | stabledisease | 100 % | NED (13 mo) |